Immune checkpoint inhibitors, such as anti-PD-1 and anti-PD-L1, have been approved by the Food and Drug Administration (FDA) for the treatment of various types of cancer, resulting in durable tumor regression and prolonged survival (30, 31). This evidence concerns the gene PDCD1 and neoplasm.